Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_1

50%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

completed375%

terminated125%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_1

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

NCT00878722

completedphase_1

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

NCT00878800

terminatedphase_2

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

NCT00431340

completedphase_2

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

NCT00131261

Clinical Trials (4)

Showing 4 of 4 trials

NCT00878722Phase 1

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

Completed

NCT00878800Phase 1

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

Completed

NCT00431340Phase 2

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Terminated

NCT00131261Phase 2

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4